>> Type 1 diabetes (T1D) is an autoimmune disease characterized by the destruction of insulin-producing beta cells in the pancreas
Express | Open up a new model of targeted RNA, Janssen reached a cooperation of over 1 billion US dollars
Time of Update: 2022-03-02
On February 17, 2022, Remix Therapeutics announced an R&D collaboration with Janssen, a subsidiary of Johnson & Johnson, to use Remix's REMaster drug discovery platform to develop small molecule therapeutics that modulate RNA processing .
A new strategy for epigenetic therapy of prostate cancer based on targeting SWI/SNF chromatin remodeling complex ATPase
Time of Update: 2022-02-24
Chinnaiyan at the Michigan Center for Translational Pathology (MCTP) at the University of Michigan School of Medicine published in Nature a report titled Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer research paper .
Myeloma New Vision cilta-cel, a CAR-T therapy targeting BCMA for RRMM patients (CARTITUDE-1 study)
Time of Update: 2022-01-10
apheresis is completed . Cilta-cel is prepared by transducing a lentiviral vector expressing anti-BCMA-CAR (including two BCMA binding domains, a CD3-ζ signal domain, and a 4-1BB
The latest data of the new AAV9-mediated RNA targeting system is released, which can correct
Time of Update: 2021-12-04
▲ DM1 disease development process (picture source: Locanabio official website) The modular RNA binding protein system developed by the CorRECTX™ platform can modify RNA through a variety of mechanisms, such as cutting, splicing, gene replacement, translation enhancement and editing .
Philippine's annual agricultural value added target is lowered to 1%
Time of Update: 2021-12-01
%. To 1% . According to a report by the Philippine Business Mirror on November 9, Philippine Deputy Minister of
Phase 3 clinical trial of TROP2 targeting ADC/blockbuster PD-1 antibody for the first-line treatment of lung cancer is about to start
Time of Update: 2021-11-02
Daiichi Sankyo will lead a global phase 3 clinical trial to evaluate the antibody-conjugated drug (ADC) datopotamab deruxtecan (Dato-DXd) that targets TROP2 in combination with Merck’s blockbuster PD-1 inhibitor Keytruda.
Focus on drug targets: PD-1 / PD-L1, when will the internal volume be closed?
Time of Update: 2021-11-01
monoclonal antibodies are in production > As a broad-spectrum immunosuppressant, PD-1/PD-L1 monoclonal antibody has achieved good clinical results in many tumors, but its overall response rate is relatively low at about 20%, which can
175 million yuan Xinlitai introduced GLP-1/GCGR dual target agonist to join the new track of hypoglycemic
Time of Update: 2021-10-23
(3) If the product is sold in mainland China, if the annual net sales of the product reaches the agreed amount for the first time, the company will pay the sales milestone .
A new target for the treatment of type 1 diabetes?
Time of Update: 2021-10-22
Edited by Yimaitong, please do not reprint without authorization . Patients with type 1 diabetes need to receive insulin replacement
Target PD-1 and LAG-3!
Time of Update: 2021-09-20
for a new class 1 drug RO7247669 injection has obtained an implied license for a clinical trial and is intended to be developed for the treatment of liver cancer . Public information shows
Sanofi's $1 billion bet on new targets, which strong doctor on the multiple myeloma circuit, Mai Meng broke the news
Time of Update: 2021-08-10
with Lyell Immunopharma GPRC5D as a new target for multiple myeloma. On March 27, 2019, researchers from Eureka Therapeutics, MSKCC and Juno Therapeutics were in Science A proof-of-concept research result entitled "GPRC5D is a target
CRISPR technology knocks out PD-1, and the targeted insertion of CD19 CAR-T completes the first patient's drug delivery. Medical Meng broke the news
Time of Update: 2021-08-09
Caribou was co-founded by Nobel Laureate Professor Jennifer Doudna, aiming to use RNA-DNA hybrid sequence-mediated CRISPR gene editing system (chRDNA) to develop allogeneic cell therapy with potentially transformative effects on patients .
https:// -trial-evaluating-cb-010-a-crispr-edited-allogeneic-anti-cd19-car-t-cell-therapy-in-patients-with-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma /2.
Express simultaneously targets TIGIT, PD-1 and PVRIG three immune checkpoints, and the combined therapy completes the first case of administration
Time of Update: 2021-08-06
"Reference:  Compugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo® and Bristol Myers Squibb's Anti-TIGIT Antibody, BMS-986207.
Simultaneously targeting TIGIT, PD-1 and PVRIG immune checkpoint combination therapy to complete the first case of administration
Time of Update: 2021-08-02
Retrieved July 19, 2021, from https:// /il/news-releases/compugen-doses-first-patient-in-phase-12-triple-combination-cohort-expansion-of-com701-with-opdivo-and-bristol-myers-squibbs-anti-tigit-antibody -bms-986207-301336286.
A new target for immunotherapy-NKG2A, which targets NK cells and can act synergistically with PD-1/L1
Time of Update: 2021-06-30
Therefore, the development of new NKG2A antibodies is expected to complement existing immunotherapy and better treat cancer patients .
Cell's important finding: The presence of type I natural antibodies similar to 2G12 antibodies in the human body may become a new target for HIV-1 vaccines
Time of Update: 2021-06-22
The author only tested the reactivity of this FDG antibody to recombinant HIV-1 Env and SARS-CoV-2 S proteoglycans, but this may exclude other types of polysaccharide forms in the body .